Insider Selling: Tempus AI (NASDAQ:TEM) CAO Sells $306,341.75 in Stock

Tempus AI, Inc. (NASDAQ:TEM) CAO Ryan Bartolucci sold 6,175 shares of the company’s stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $49.61, for a total value of $306,341.75. Following the completion of the transaction, the chief accounting officer owned 67,866 shares in the company, valued at $3,366,832.26. This represents a 8.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Trading Up 9.1%

Shares of Tempus AI stock opened at $72.69 on Friday. The stock has a 50 day moving average of $52.93 and a 200 day moving average of $51.36. The company has a debt-to-equity ratio of 3.06, a quick ratio of 3.16 and a current ratio of 3.30. The firm has a market capitalization of $13.12 billion, a price-to-earnings ratio of -50.48 and a beta of 3.58. Tempus AI, Inc. has a fifty-two week low of $40.77 and a fifty-two week high of $104.32.

Tempus AI (NASDAQ:TEM) last posted its earnings results on Thursday, July 30th. The company reported ($0.04) EPS for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.10. Tempus AI had a negative return on equity of 50.28% and a negative net margin of 17.77%.The company had revenue of $382.49 million for the quarter, compared to the consensus estimate of $379.69 million. During the same quarter in the previous year, the business earned ($0.22) earnings per share. The company’s revenue for the quarter was up 21.6% on a year-over-year basis. As a group, research analysts predict that Tempus AI, Inc. will post -1.38 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on TEM shares. Stifel Nicolaus decreased their target price on shares of Tempus AI from $60.00 to $50.00 and set a “hold” rating on the stock in a research report on Monday, August 3rd. Lake Street Capital cut shares of Tempus AI to a “hold” rating in a research report on Monday, July 20th. Wolfe Research initiated coverage on shares of Tempus AI in a research note on Tuesday, June 2nd. They issued a “peer perform” rating on the stock. Piper Sandler lowered their price objective on shares of Tempus AI from $58.00 to $56.00 and set a “neutral” rating for the company in a research report on Tuesday, August 4th. Finally, Wall Street Zen upgraded shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. Nine analysts have rated the stock with a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $65.69.

Hedge Funds Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of TEM. Royal Bank of Canada increased its stake in Tempus AI by 201.2% during the first quarter. Royal Bank of Canada now owns 25,988 shares of the company’s stock worth $1,253,000 after purchasing an additional 17,359 shares during the period. Rhumbline Advisers acquired a new position in shares of Tempus AI in the first quarter valued at approximately $116,000. Prudential Financial Inc. acquired a new position in shares of Tempus AI in the second quarter valued at approximately $276,000. Russell Investments Group Ltd. increased its stake in Tempus AI by 21.3% during the 2nd quarter. Russell Investments Group Ltd. now owns 6,527 shares of the company’s stock worth $415,000 after buying an additional 1,146 shares during the period. Finally, Invesco Ltd. increased its stake in Tempus AI by 2,926.6% during the 2nd quarter. Invesco Ltd. now owns 211,621 shares of the company’s stock worth $13,446,000 after buying an additional 204,629 shares during the period. 24.22% of the stock is currently owned by hedge funds and other institutional investors.

Tempus AI News Summary

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: BTIG raised its price target for Tempus AI to $80 from $70 and maintained a “Buy” rating. The higher target strengthens the bullish case and provides a near-term catalyst for the stock. BTIG raises Tempus AI price target
• Positive Sentiment: Investor attention is building around Tempus AI’s planned approximately $1.5 billion all-stock acquisition of Personalis. The deal could expand Tempus’ genomic-data, cancer-testing and drug-development capabilities, potentially increasing its strategic value in precision medicine. Tempus AI biotech deal attracts investor attention
• Positive Sentiment: Merck and Moderna’s cancer-vaccine trial developments have heightened interest in oncology data and genomic testing. The connection to Tempus is indirect, but the news reinforces the company’s cancer-data and personalized-treatment growth narrative. Tempus AI stock move and Merck-Moderna trial news
• Positive Sentiment: Trading activity in TEM call options was unusually high, with reported volume roughly 57% above normal. This indicates bullish speculation and may be amplifying the stock’s momentum, though options activity can also increase volatility.
• Neutral Sentiment: The stock has moved above its 50-day and 200-day moving averages, raising the possibility of momentum buying or a short squeeze. That technical strength could support further gains, but it also increases the risk of a sharp reversal.
• Negative Sentiment: Tempus AI’s CEO, CFO, EVP and chief accounting officer sold shares, with the largest reported transaction involving CEO Eric Lefkofsky. The sales reduced executives’ holdings and may concern investors, but they were conducted under pre-arranged Rule 10b5-1 plans to cover tax withholding on vested equity awards, making them a weaker bearish signal than discretionary selling.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.